施贵宝公司公布了一项关键临床数据,其新型药物Celmod Mezigdomide在治疗复发或难治性多发性骨髓瘤患者时,展现出显著优势。与当前标准治疗方案相比,该药物能将患者疾病进展或死亡的风险降低超过50%。这一突破性结果为这一难治性血液肿瘤的治疗带来了新的希望。
施贵宝公司公布了一项关键临床数据,其新型药物Celmod Mezigdomide在治疗复发或难治性多发性骨髓瘤患者时,展现出显著优势。与当前标准治疗方案相比,该药物能将患者疾病进展或死亡的风险降低超过50%。这一突破性结果为这一难治性血液肿瘤的治疗带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.